Key result
SGLT2 inhibitors provide a global benefit in patients with heart failure with reduced ejection fraction.
Key points are not available for this paper at this time.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Brownell et al. (2022) studied this question. SGLT2 inhibitors provide a global benefit in patients with heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: